10Y annualized return is
negative
at -4.1% per year
INCY has met or exceeded earnings expectations in
few
recent quarters (4/10)
Moderate Price-to-Sales Ratio
Strong Gross Profit Margin
Extremely High Price-to-Earnings Ratio
High EV/EBITDA Ratio
Get access to all key takeaways, detailed financial metrics, and comprehensive stock analysis with our premium subscription.
Already have an account? Sign in
Incyte demonstrates a strong business quality with solid revenue growth, a diversified product portfolio, and a healthy financial position. Future prospects appear promising with multiple product launches and a robust pipeline, although pricing pressures and market competition could pose challenges.
Analysis Date: February 10, 2025
Last Updated: May 29, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Incyte Corporation is a biotechnology company that creates medicines to treat serious diseases, especially types of cancer and blood disorders. They have developed several important drugs, including JAKAFI, which helps patients with certain blood cancers. Incyte is also working on new treatments that are still being tested to help patients with various types of cancer and other health conditions. The company partners with other organizations to advance their research and bring new therapies to market.
Streams of revenue
Geographic Distribution
Core Products
Business Type
Business to Business
Competitive Advantages
Discover all competitive advantages and strategic moats that protect INCY's market position.
View Premium AnalysisKey Business Risks
Get comprehensive insight into all key business risks that could impact INCY's performance.
Access Full Risk AnalysisTrailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Access detailed profitability metrics with visual gauges and benchmarks
Access detailed analysis of profitability strengths and positive performance indicators
Upgrade to PremiumAccess detailed analysis of profitability weaknesses and areas of concern
Upgrade to PremiumFinancial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Access detailed financial health metrics with visual gauges and risk assessments
Access detailed analysis of financial health strengths and stability indicators
Upgrade to PremiumAccess detailed analysis of financial health weaknesses and risk factors
Upgrade to PremiumMeeting Expectations
Higher values indicate better execution and credibility
Recent Results
View complete earnings history and detailed performance analysis
Upgrade to PremiumEPS
Revenue
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Get complete insider sentiment analysis with detailed trading patterns, sentiment indicators, and trend insights
